Lenalidomida Olainfarm

Lenalidomide, the active ingredient in Lenalidomida Olainfarm, is an immunomodulatory drug (IMiD) presented as an oral formulation for systemic use. It is employed in the treatment of certain hematologic malignancies, notably multiple myeloma and myelodysplastic syndromes with a 5q chromosomal deletion, in adult patients.

GNH USA supplies Lenalidomida Olainfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product complies with EU quality standards and is manufactured under GMP conditions. It is distributed through a secure, temperature‑controlled logistics network.

Lenalidomide is employed in hematologic oncology to modulate the immune environment, inhibit angiogenesis, and promote apoptosis of malignant cells, particularly in plasma‑cell and myeloid disorders.

- Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic syndromes with 5q deletion: induces transfusion independence and cytogenetic remission in affected individuals.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count, increasing infection risk. - Thrombocytopenia: reduced platelet levels, may cause bruising or bleeding. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism, potentially life‑threatening. - Severe neutropenia: profound drop in neutrophils leading to febrile infections. - Secondary primary malignancies: emergence of new cancers during therapy. - Hepatic toxicity: elevated liver enzymes or hepatitis.

When prescribing Lenalidomide, clinicians should observe several safety considerations to minimize risks. - Pregnancy contraindication: drug is teratogenic (Category X) and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Renal and hepatic impairment: adjust dose or monitor closely in patients with organ dysfunction. - Contraception requirement: both male and female patients of reproductive potential must use effective contraception during treatment and for a defined period after discontinuation. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Lenalidomide interacts with several medicines; awareness of major and moderate interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Thalidomide co‑administration: combined teratogenic risk and overlapping toxicities. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce lenalidomide exposure. - Anticoagulants (warfarin, direct oral anticoagulants): increase risk of severe thrombosis or bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma levels modestly. - Live vaccines: reduced efficacy and potential infection risk while on therapy.